Mandatory Review of HHS Agencies' Annual Accounting of National Drug Control Program Funds
The Office of National Drug Control Policy circular, Accounting of Drug Control Funding and Performance Summary requires agencies expending funds on National Drug Control Program activities to submit an accounting of the expenditure of such funds made during the previous fiscal year (21 U.S.C. § 1704). The policy also requires that an agency submit with its annual accounting an authentication provided by the agency's OIG that expresses a conclusion on the reliability of the agency's assertions. The circular states that if in an agency's prior year drug-related obligations were less than $50 million, the agency would not be subject to these authentication requirements. We will review how HHS agencies complied with this circular and will submit the authentication with respect to the HHS agencies' annual accounting, beginning with FY 2020, once every three years.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|October 2020||ACF, CDC, CMS, HRSA, IHS, NIH, SAMHSA||Mandatory Review of HHS Agencies' Annual Accounting of National Drug Control Program Funds||Office of Audit Services||W-00-21-52312||2021|